Head neck cancer new drug development progress

Share：

Head neck cancer new drug development progress

Clinical trial for head neck cancer (Project ID: LUKACT-01-01; Project title: Study on the use of activated T cells for the treatment of locally advanced head neck squamous cell carcinoma after surgery section and combined radiotherapy and chemotherapy) was approved by TFDA in 2018. We enrolled the first volunteer in Taipei Veterans General Hospital. This trial is currently undergoing a protocol amendment.

Treatment

Drug discovery

preclinical research

phase I

phase II

phase III

NDA/Approved

Activated T cell
injection

🔵

📋Clinical Trial Name

Study on the use of activated T cells for the treatment of locally advanced head neck squamous cell carcinoma after surgery section and combined radiotherapy and chemotherapy.

Trial Applicant	Lukas Biomedical Inc.
Trial Sponsor	Same as the trial applicant
Trial Protocol Number	LUKCT-01-01
Approval Document Number	1066038845
Approval Registration Date	27 April 2018
Estimated Trial Period	1 December 2021 to 31 December 2026

Trial Objectives

To evaluate the safety and immune cell expression change of autologous peripheral blood-derived activated T cells used for the treatment of locally advanced head and neck squamous cell carcinoma.

Trial Phase

Phase Ⅱ

Drug Name

Activated T cell

Proposed Indications

Head and Neck Cancers

CDE TAIWAN